ImportantMRK
Explain this story: Merck & Co., Inc. (NYSE:MRK) Stock Price Target Raised at Scotiabank
Scotiabank has increased its price target for Merck & Co., Inc. (NYSE:MRK) from $155.00 to $180.00, reiterating a "sector outperform" rating and suggesting a 22.81% upside. This follows a trend of positive analyst sentiment, with the company holding a "Moderate Buy" consensus rating. Merck recently surpassed quarterly earnings and revenue expectations, although insider selling of nearly $30 million was noted over the past 90 days.
OtherMarketBeatSector and industry: HealthcareDrug ManufacturersTell me moreShow less
We have not explained this story yet. The original headline, summary and link are below.
Scotiabank has increased its price target for Merck & Co., Inc. (NYSE:MRK) from $155.00 to $180.00, reiterating a "sector outperform" rating and suggesting a 22.81% upside. This follows a trend of positive analyst sentiment, with the company holding a "Moderate Buy" consensus rating. Merck recently surpassed quarterly earnings and revenue expectations, although insider selling of nearly $30 million was noted over the past 90 days.
Article tone: Positive This describes the words the journalist used. It is not a prediction, and not advice.
Published Sep 29, 2026, 11:27 ET · on this site +1h 21m